REG - Citadel Group Mural Oncology PLC - Form 8.3 - Mural Oncology plc

RNS Number : 4280W Citadel Group 22 August 2025 Ap27FORM 8.3IRISH TAKEOVER PANELOPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVERRULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE1. KEY INFORMATION(a) Full name of discloserCitadel Group(b) Owner or controller of interests and short positions disclosed, if different from 1(a)The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.N/A(c) Name of offeror/offeree in relation to whose relevant securities this form relatesUse a separate form for each offeror/offereeMURAL ONCOLOGY PLC(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree (Note 1)N/A(e) Date position held/dealing undertakenFor an opening position disclosure, state the latest practicable date prior to the disclosure21 August 2025(f) In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer?If it is a cash offer or possible cash offer, state "N/A"N/A2. INTERESTS AND SHORT POSITIONSIf there are interests and short positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.Ap28Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)(Note 2)Class of relevant security (Note 3)Common Stock ISIN IE000LK2BOB4$0.01 ordinary sharesInterestsShort positionsNumber%Number%(1) Relevant securities owned and/or controlled375,8162.1600.00(2) Cash-settled derivatives00.00230.00(3) Stock-settled derivatives (including options) and agreements to purchase/ sell28,1000.16212,8001.22Total403,9162.33212,8231.22All interests and all short positions should be disclosed.Details of options including rights to subscribe for new securities and any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8.3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE (Note 4)Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.The currency of all prices and other monetary amounts should be stated.(a) Purchases and salesClass of relevantsecurityPurchase/saleNumber ofsecuritiesPrice per unit (Note 5) CommonBuy Transaction622.0700 USD CommonBuy Transaction9002.0711 USD CommonBuy Transaction122.0717 USD CommonBuy Transaction232.0717 USD CommonBuy Transaction2502.0718 USD CommonBuy Transaction92.0722 USD CommonBuy Transaction1,8842.0750 USD CommonBuy Transaction1162.0751 USD CommonBuy Transaction3,1062.0752 USD CommonBuy Transaction1642.0787 USD CommonBuy Transaction202.0790 USD CommonBuy Transaction2,5102.0800 USD CommonBuy Transaction202.0810 USD CommonBuy Transaction6,3212.0816 USD CommonBuy Transaction3572.0884 USD CommonBuy Transaction7,9672.0900 USD CommonSell Transaction2,1332.0700 USD CommonSell Transaction51,3092.0701 USD CommonSell Transaction15,1142.0703 USD CommonSell Transaction6,3002.0708 USD CommonSell Transaction9,9692.0708 USD CommonSell Transaction6,0002.0708 USD CommonSell Transaction3,6522.0711 USD CommonSell Transaction3,1862.0713 USD CommonSell Transaction12.0743 USD CommonSell Transaction1282.0750 USD CommonSell Transaction472.0755 USD CommonSell Transaction52.0760 USD CommonSell Transaction402.0790 USD CommonSell Transaction3242.0793 USD CommonSell Transaction4242.0794 USD CommonSell Transaction2,8122.0800 USD CommonSell Transaction1002.0850 USD CommonSell Transaction122.0883 USD CommonSell Transaction1602.0887 USD CommonSell Transaction4,6232.0888 USD CommonSell Transaction5752.0894 USD CommonSell Transaction202.0895 USD CommonSell Transaction4712.0900 USDAp29(b) Cash-settled derivative transactionsClass of relevant securityProduct description e.g. CFDNature of dealing e.g. opening/ closing a long/ short position, increasing/ reducing a long/ short positionNumber of reference securities (Note 6)Price per unit (Note 5)(c) Stock-settled derivative transactions (including options)(i) Writing, selling, purchasing or varyingClass of relevant securityProduct description e.g. call optionWriting, purchasing, selling, varying etc.Number of securities to which option relates (Note 6)Exerciseprice per unitType e.g. American, Europeanetc.Expiry dateOption moneypaid/ received per unit(ii) ExerciseClass of relevant securityProduct description e.g. call optionExercising/ exercised againstNumber of securitiesExercise price per unit (Note 5)(d) Other dealings (including transactions in respect of new securities) (Note 3)Class of relevant securityNature of dealing e.g. subscription, conversion, exerciseDetailsPrice per unit (if applicable) (Note 5)Ap304. OTHER INFORMATION(a) Indemnity and other dealing arrangementsDetails of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer.Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"None(b) Agreements, arrangements or understandings relating to options or derivativesFull details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.None(c) AttachmentsIs a Supplemental Form 8 attached?YESDate of disclosure22 August 2025Contact namePaula SantosTelephone number020 7645 9700Public disclosures under Rule 8.3 of the Rules must be made to a Regulatory Information Service.Ap32SUPPLEMENTAL FORM 8IRISH TAKEOVER PANELDISCLOSURE UNDER RULE 8.1, RULE 8.3, RULE 38.5(b) ANDRULE 38.6 OF THE IRISH TAKEOVER PANEL ACT, 1997,TAKEOVER RULES, 2022DETAILS OF OPEN STOCK-SETTLED DERIVATIVE (INCLUDINGOPTION) POSITIONS, AGREEMENTS TO PURCHASE OR SELL ANDRIGHTS TO SUBSCRIBE FOR NEW SECURITIES1. KEY INFORMATIONFull name of person making disclosure:Citadel GroupName of offeror/offeree in relation to whose relevant securities the disclosure relates:MURAL ONCOLOGY PLC2. STOCK-SETTLED DERIVATIVES (INCLUDING OPTIONS)Class of relevant securityProduct description e.g. call optionWritten or purchasedNumber of securities towhich optionor derivative relatesExercise price per unitType e.g. American, European etc.Expiry dateCommonPut OptionPurchased-16,2002.5 USDAmerican19/09/2025CommonCall OptionPurchased8,8002.5 USDAmerican20/03/2026CommonPut OptionPurchased-2005.0 USDAmerican19/09/2025CommonCall OptionPurchased8005.0 USDAmerican19/12/2025CommonCall OptionPurchased9005.0 USDAmerican20/03/2026CommonPut OptionPurchased-80,7002.5 USDAmerican15/01/2027CommonCall OptionPurchased2,0007.5 USDAmerican20/03/2026CommonCall OptionPurchased14,6005.0 USDAmerican19/09/2025CommonPut OptionPurchased-3,1002.5 USDAmerican19/12/2025CommonPut OptionSold1,0002.5 USDAmerican17/10/2025CommonCall OptionSold-17,7002.5 USDAmerican19/09/2025CommonCall OptionSold-49,1005.0 USDAmerican15/01/2027CommonCall OptionSold-2007.5 USDAmerican19/09/2025CommonCall OptionSold-4,0002.5 USDAmerican19/12/2025CommonCall OptionSold-41,6002.5 USDAmerican15/01/20273. AGREEMENTS TO PURCHASE OR SELLFull details should be given so that the nature of the interest or position can be fully understood:Ap334. RIGHTS TO SUBSCRIBE FOR NEW SECURITIES (INCLUDING DIRECTORS' AND OTHER EMPLOYEE OPTIONS)Class of relevant security in relation to which subscription right exists:Details, including nature of the rights concerned and relevant percentages:It is not necessary to provide details on a Supplemental Form with regard to cash-settled derivatives.The currency of all prices and other monetary amounts should be stated.For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel.References in these notes to "the Rules" are to the Irish Takeover Panel Act, 1997, Takeover Rules, 2022.This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END ITPPKBBPOBKKCFB